HOME About Santen News IR Information Products Careers  
 
IR Information
Financial Summary
Financial Documents
IR Events
Stock Information
Corporate
Governance
IR Contact
 
IR Information  > 

Financial Summary
Net Sales of the year ended March 2012 114,416 million Yen Net Income of the year ended March 2012 17,160 million yen
Retrn on Equity(ROE) of the year ended March 2012 10.7% R&D Costs and Ratio of R&D Costs to Net Sales Year ended March 2012 R&D Costs 17,225 million yen Ratio of R&D Costs to Net Sales 15.1%
Sales by Business Segment 81.8% Prescription Ophthalmic Pharmaceuticals 8.7% Prescription Anti-rheumatic Pharmaceuticals 4.0% OTC Pharmaceuticals 2.2% Medical Devices

Back to top

Five-year Summary of Selected Financial Data


Five-year Summary of Selected Financial Data


Back to top 		 
Research & Development
Share Price
20-minute delayed share price and charts.
Provided by Nomura Securities Co.,Ltd.
Download Adobe® Reader® to view PDF files.
  Get Adobe Reader